Clinical trial · Observational
hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation
Establishment of Clinical Applicable Human Amniotic Epithelial Cell Products and Its Preliminary Application in Allogeneic Hematopoietic Stem Cell Transplantation
NCT03759899CI-TRIAL-00047440unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Cell counts of T cells, NK cells, B cells and monocytes
- timeFrame
- Day 7
- description
- proliferation and apoptosis of T cells, NK cells, B cells and monocytes in peripheral blood of patients
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * leukemia patients with allogeneic HSCT * KFS score \>90 * after transplantation, the patient was implanted (peripheral blood neutrophil absolute value \>500/ul for 3 consecutive days) * no uncontrolled infection after transplantation * activity II above aGVHD * patients agreed to participate in the study Exclusion Criteria: * patients refused to participate in the study * patients have poor compliance * has received hormone therapy * patients had serious heart, lung, liver, kidney and other vital organs damage * researchers believe that patients who are not suitable for observation study
References
Publications (0)
Data not yet available
No reference posted for this study.